Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial

Abstract

There was no clinical difference between the effect of preventive administration of ulinastatin and that of gabexate mesylate on the incidence of post-ERCP pancreatitis. Ulinastatin may be equivalent in efficacy to gabexate for reducing the incidence of post-ERCP pancreatitis.

The effects of a new human leukocyte elastase inhibitor (recombinant guamerin) on cerulein-induced pancreatitis in rats

“…These results are little different previously [7,8]. Therefore, we suggested ONO-5046, a specific (ERCP) pancreatitis [25,26]. The effectiveness in groups of [26].…”

Protease inhibitors for preventing complications associated with ERCP: an updated meta-analysis

“…Agreement between reviewers regarding selection of relevant articles was 100%. A total of 10 articles were excluded [26][27][28][29][30][31][32][33][34][35] : 10 articles met the exclusion criteria, 4 used protease inhibitors in both groups, [26][27][28][29] and 2 evaluated nonclinical outcomes, 30,31 2 review, 32,33 1 comment, 34 and 1 postoperative study. 35 We therefore analyzed 18 articles with a total of 4966 subjects (Online Table 1, available at www.giejournal.…”

Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy

“…In multicenter randomized clinical trial, none of the 204 patients in the ulinastatin group developed adverse events related to short-term ulinastatin administration as prophylactic agent of post-ERCP pancreatitis [2]. In addition, no serious adverse effects of ulinastatin administration have been observed in the series reported [16,17].…”